New therapies in the treatment of high cholesterol: An argument to return to goal-based lipid guidelines

JAMA - Journal of the American Medical Association

Volumn 314, Issue 14, 2015, Pages 1443-1444

  Shrank, William H ^a   Barlow, Jane F ^a   Brennan, Troyen A ^a  

^a CVS Caremark   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTILIPEMIC AGENT; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

BUDGET; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERLIPIDEMIA; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; UNITED STATES; ANTAGONISTS AND INHIBITORS; BLOOD; ECONOMICS; EUROPE; HYPERLIPIDEMIAS;

CHOLESTEROL, LDL; DRUG COSTS; EUROPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; UNITED STATES;

EID: 84944080845     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.10017     Document Type: Note

References (9)

1. Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia. Ann Intern Med. 2015;163(1):40-51.
2. Mozaffarian D, Benjamin EJ, Go AS, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2015 update. Circulation. 2015;131(4):e29-e322.
3. Brennan T, Shrank W. New expensive treatments for hepatitis C infection. JAMA. 2014;312(6):593-594.
4. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol. 2014;63(25 Pt B):2889-2934.
5. Hayward RA, Krumholz HM. Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health. Circ Cardiovasc Qual Outcomes. 2012;5(1):2-5.
6. Pandya A, Sy S, Cho S, Weinstein MC, Gaziano TA. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA. 2015;314(2):142-150.
7. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387-2397.
8. Nordestgaard BG, Chapman MJ, Humphries SE, et al; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J. 2013;34(45):3478-90a.
9. Jellinger PS, Smith DA, Mehta AE, et al. American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2012;18(suppl 1):1-78.